NCT05533801View on ClinicalTrials.gov

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

January 6, 2023

Study Completion Date

January 6, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Lecanemab

Lecanemab will be administered subcutaneously using a vial and syringe.

DRUG

Lecanemab

Lecanemab will be administered subcutaneously using AI.

Trial Locations (1)

92801

Anaheim Clinical Trials, Anaheim

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY